Mahmut Emre Yildirim (Mahmut Emre Yıldırım)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 13

Top Topics

Peritoneal Dialysis

Prognostic Factors

Metastatic Breast Cancer

Top Venues

Medicina (Kaunas, Lithuania)

Scientific reports

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Emre Kudu, Goncagul Akdag, Mahmut Emre Yildirim
Evaluation of emergency department visits and immune-related adverse effects (irAEs) in patients treated with nivolumab. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 32 (10) (2024)
Oguzcan Kinikoglu, Hatice Odabaş, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yildirim, Hamit Bal, Tuğba Kaya, Salih Tünbekici, Deniz Işık, Tuğba Başoğlu, Mahmut Emre Yildirim, Nedim Turan
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina (Kaunas, Lithuania) 60 (6) (2024)
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Eyyüp Cavdar, Oguzcan Kinikoglu, Sila Oksuz, Hacer Sahika Yildiz, Aysun Kucukoz Uzun, Deniz Işık, Heves Surmeli, Tugba Basoglu Tuylu, Ozlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients. Cancers 16 (14) (2024)
Oguzcan Kinikoglu, Hatice Odabaş, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yildirim, Hamit Bal, Tuğba Kaya, Salih Tünbekici, Deniz Işık, Tuğba Başoğlu, Mahmut Emre Yildirim, Nedim Turan
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina (Kaunas, Lithuania) 60 (6) (2024)
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Eyyüp Cavdar, Oguzcan Kinikoglu, Sila Oksuz, Hacer Sahika Yildiz, Aysun Kucukoz Uzun, Deniz Işık, Heves Surmeli, Tugba Basoglu Tuylu, Ozlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients. Cancers 16 (14) (2024)
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Zeynep Yüksel Yasar, Hamit Bal, Oguzcan Kinikoglu, Sila Oksuz, Ugur Ozkerim, Salih Tunbekici, Hacer Sahika Yildiz, Özkan Alan, Sermin Coban Kokten, Deniz Işık, Heves Surmeli, Tugba Basoglu Tuylu, Ozlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy. Scientific reports 14 (1) (2024)
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Zeynep Yüksel Yasar, Hamit Bal, Oguzcan Kinikoglu, Sila Oksuz, Ugur Ozkerim, Salih Tunbekici, Hacer Sahika Yildiz, Özkan Alan, Sermin Coban Kokten, Deniz Işık, Heves Surmeli, Tugba Basoglu Tuylu, Ozlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy. Scientific reports 14 (1) (2024)
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Zeynep Yüksel Yasar, Hamit Bal, Oguzcan Kinikoglu, Sila Oksuz, Ugur Ozkerim, Salih Tunbekici, Hacer Sahika Yildiz, Özkan Alan, Sermin Coban Kokten, Deniz Işık, Heves Surmeli, Tugba Basoglu Tuylu, Ozlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy. Scientific reports 14 (1) (2024)
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Eyyüp Cavdar, Oguzcan Kinikoglu, Sila Oksuz, Hacer Sahika Yildiz, Aysun Kucukoz Uzun, Deniz Işık, Heves Surmeli, Tugba Basoglu Tuylu, Ozlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients. Cancers 16 (14) (2024)
Sedat Yildirim, Özkan Alan, Zeynep Yüksel Yasar, Tugba Kaya, Goncagul Akdag, Oguzcan Kinikoglu, Gonca Gul Gecmen, Alper Yaşar, Deniz Işık, Heves Surmeli, Tugba Basoglu, Ozlem Nuray Sever, Mahmut Emre Yildirim, Hatice Odabaş, Nedim Turan
Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis. Medicina (Kaunas, Lithuania) 60 (8) (2024)
Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten, Hacı Mehmet Türk, Zuhat Urakci, Çağatay Arslan, Sinemis Çelik, Faysal Dane, Mehmet Ali Nahit Şendur, Cemil Bilir, Bülent Karabulut, Irfan Cicin, Erdem Cubukcu, Mustafa Karaca, Melike Ozcelik, Mustafa Yıldırım, Eda Tanrikulu, Ahmet Alacacioglu, Özgür Açıkgöz, Başak Öven, Çağlayan Geredeli, Timucin Çil, Hakan Harputluoğlu, Umut Kefeli, Oktay Bozkurt, Deniz Tural, Abdullah Sakin, Şuayip Yalçın, Mahmut Gumus
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Goncagul Akdag, Deniz Işık, Akif Dogan, Sedat Yildirim, Oguzcan Kinikoglu, Alper Topal, Sila Oksuz, Ezgi Turkoglu, Heves Surmeli, Tugba Basoglu, Ozlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer? Medicina (Kaunas, Lithuania) 60 (8) (2024)
Goncagul Akdag, Özkan Alan, Akif Dogan, Zeynep Yüksel Yasar, Sedat Yildirim, Oguzcan Kinikoglu, Emre Kudu, Heves Surmeli, Hatice Odabaş, Mahmut Emre Yildirim, Nedim Turan
Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience. World journal of urology (2023)